This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by NETELENBOS, J. C Articles by HACKENG, W. H. L. Search for Related Content PubMed PubMed Citation Articles by NETELENBOS, J. C Articles by HACKENG, W. H. L.

Absence of Effect of 24,25-Dihydroxyvitamin D₃ in Primary Hyperparathyroidism

Department of Internal Medicine, Academisch Ziekenhuis Vrije Universiteit Amsterdam, The Netherlands
Bergwegziekenhuis Rotterdam, The Netherlands

Address correspondence and requests for reprints to: Dr. J. C. Netelenbos, Department of Internal Medicine, Academisch Ziekenhuis Vrije Universiteit, P.O. Box 7057,1007 MB, Amsterdam, The Netherlands.

Nineteen patients with primary hyperparathyroidism were treated with 25 µg 24,25-dihydroxyvitamin D₃ or placebo daily for 3 months according to double-blind cross-over protocol. Serum immunoreactive PTH, total and ionized calcium, urinary calcium excretion, tubular reabsorption of phosphate/glomerular filtrate, and urinary hydroxyproline excretion did not change significantly. Serum 24,25-dihydroxyvitamin D₃ levels increased significantly from 1.4 ± 2.2 (SD) nmol/liter to 38 ± 11 nmol/liter during the treatment period. Serum 25-hydroxyvitamin D₃ and 1,25-dihydroxyvitamin D₃ levels did not change. We conclude that pharmacological doses of 24,25-dihydroxyvitamin D₃ have no suppressive effect on parathyroid function in primary hyperparathyroidism.

Received November 15, 1985.